Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 170

Showing 26-50 of 170 citing articles:

Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis
Nina B. Curkovic, Kun Bai, Fei Ye, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 340-340
Open Access | Times Cited: 9
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs
Stefano Fogli, Camillo Porta, Marzia Del Re, et al.
Cancer Treatment Reviews (2020) Vol. 84, pp. 101966-101966
Closed Access | Times Cited: 60
Reverting Immune Suppression to Enhance Cancer Immunotherapy
Bella S. Guerrouahen, Cristina Maccalli, Chiara Cugno, et al.
Frontiers in Oncology (2020) Vol. 9
Open Access | Times Cited: 59
Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data
Michael Moran, Dana J. Nickens, Katherine Adcock, et al.
Targeted Oncology (2019) Vol. 14, Iss. 4, pp. 405-416
Open Access | Times Cited: 55
Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis
Keiichiro Mori, Hadi Mostafaei, Noriyoshi Miura, et al.
Cancer Immunology Immunotherapy (2020) Vol. 70, Iss. 2, pp. 265-273
Open Access | Times Cited: 53
Current State of Systemic Therapies for Advanced Renal Cell Carcinoma
Shuchi Gulati, Ulka N. Vaishampayan
Current Oncology Reports (2020) Vol. 22, Iss. 3
Closed Access | Times Cited: 50
Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?
Mojtaba Mollaei, Zuhair Mohammad Hassan, Fatemeh Khorshidi, et al.
Translational Oncology (2021) Vol. 14, Iss. 5, pp. 101056-101056
Open Access | Times Cited: 47
Treatment Selection in First-line Metastatic Renal Cell Carcinoma—The Contemporary Treatment Paradigm in the Age of Combination Therapy
Vishal Navani, Daniel Y.C. Heng
JAMA Oncology (2021) Vol. 8, Iss. 2, pp. 292-292
Closed Access | Times Cited: 44
Overcoming anti-PD-1/PD-L1 immune checkpoint blockade resistance: the role of macrophage, neutrophils and mast cells in the tumor microenvironment
Louis Boafo Kwantwi
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 7, pp. 3077-3091
Closed Access | Times Cited: 20
Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
Taymeyah Al‐Toubah, Michael J. Schell, Brian Morse, et al.
ESMO Open (2024) Vol. 9, Iss. 4, pp. 102386-102386
Open Access | Times Cited: 6
Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review
Vito Longo, Oronzo Brunetti, Amalia Azzariti, et al.
Cancers (2019) Vol. 11, Iss. 4, pp. 539-539
Open Access | Times Cited: 52
The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma
Rohan Garje, Josiah J. An, Austin Greco, et al.
Cancers (2020) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 48
Clinical implications of tumor-intrinsic mechanisms regulating PD-L1
Alessandro Prestipino, Robert Zeiser
Science Translational Medicine (2019) Vol. 11, Iss. 478
Closed Access | Times Cited: 45
Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
Ling Gao, Xi Yang, Yi Cheng, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 45
Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003
Arkadiusz Z. Dudek, Li Liu, Shilpa Gupta, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 11, pp. 1138-1145
Open Access | Times Cited: 39
Renal Cell Cancer and Chronic Kidney Disease
Danielle L. Saly, Meghana Eswarappa, Sarah E. Street, et al.
Advances in Chronic Kidney Disease (2021) Vol. 28, Iss. 5, pp. 460-468.e1
Closed Access | Times Cited: 37
Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma
Michael Serzan, Michael B. Atkins
Journal of Cancer Metastasis and Treatment (2021)
Open Access | Times Cited: 33
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers
Capucine Baldini, François‐Xavier Danlos, Andreea Varga, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 25
Efficacy and safety of atezolizumab plus bevacizumab versus sunitinib for metastatic renal cell carcinoma: a systematic review and meta-analysis
Xuanji Li, Zeyu Han, Xianyanling Yi, et al.
Research Square (Research Square) (2025)
Closed Access
Liver injury related to vascular endothelial growth factor tyrosine kinase inhibitors: a pharmacovigilance analysis of the USA FDA adverse event reporting system (FAERS) database
Xiang Wang, Rujie Chen, Jialin Liu, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
Alvaro Ingles Garces, Lewis Au, Robert M. Mason, et al.
Expert Opinion on Investigational Drugs (2019) Vol. 28, Iss. 8, pp. 695-708
Closed Access | Times Cited: 42
Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
Marilina García-Aranda, Maximino Redondo
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 9, pp. 2296-2296
Open Access | Times Cited: 40
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma
Simon Chowdhury, J. Infante, Robert D. Hawkins, et al.
Clinical Genitourinary Cancer (2021) Vol. 19, Iss. 5, pp. 434-446
Open Access | Times Cited: 32
Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials
Hamidreza Akhbariyoon, Yasaman Azizpour, Marjan Fakhrizadeh Esfahani, et al.
Clinical Immunology (2021) Vol. 232, pp. 108873-108873
Closed Access | Times Cited: 30
Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice
Michela Roberto, Andrea Botticelli, Martina Panebianco, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 29

Scroll to top